Liver cancer is a frequent disease. Patients with liver cancer have most of the time an underlying chronic liver disease, often without knowing it since the liver is an organ which does not trigger pain. However, it is possible to cure patients from their liver cancer when the diagnosis is done at an early stage. Therefore diagnostic tools for detecting liver cancer are of utmost importance.
Therapeutically great progresses have been realized in the last years, patients have access to more possible treatments. But the treatment of patients with liver cancer is complex.
The Swiss Foundation against Liver Cancer aims at disseminating information about this disease to increase awareness and to support research to improve the diagnosis, therapy and management of patients and families confronted with this disease.
In our recent podcast lead by Prod. Jean-François Dufour, we had the privilege of speaking with Professor Michel Ducreux, a leading expert in the field of oncology from Paris, France. The discussion focused on the evolving landscape of colorectal cancer treatment and the latest advancements that are reshaping patient care. Below you will find the
In our latest “Ask the Author” session, Professor Peter Galle presented the groundbreaking results of the CheckMate 9DW clinical trial, which explored the efficacy of the combination of nivolumab and ipilimumab versus lenvatinib or sorafenib as first-line treatments for unresectable hepatocellular carcinoma (HCC). Below you will find the video as well as the summary: Background:
In a recent “Ask the Author” session, we had the pleasure of hosting Professor Vitale from the University of Padova, Italy. Renowned for his contributions to the field of hepatocellular carcinoma (HCC), Professor Vitale discussed his latest publication, “Merits and Boundaries of the BCLC Staging and Treatment Algorithm: Learning From the Past to Improve the
